Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study.

[1]  W. Oertel,et al.  Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial , 2008, The Lancet Neurology.

[2]  Lynn Marie Trotti,et al.  Correlates of PLMs variability over multiple nights and impact upon RLS diagnosis. , 2009, Sleep medicine.

[3]  C. Guilleminault,et al.  Atlas and scoring rules , 1993 .

[4]  C Trenkwalder,et al.  A randomized controlled study of pergolide in patients with restless legs syndrome , 1999, Neurology.

[5]  W. Oertel,et al.  Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study , 2011, The Lancet Neurology.

[6]  K. Berger,et al.  Epidemiology of restless legs syndrome: the current status. , 2006, Sleep medicine reviews.

[7]  M. Partinen,et al.  Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study. , 2006, Sleep medicine.

[8]  K. Abrams,et al.  Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. , 2008, Sleep medicine.

[9]  W. Oertel,et al.  Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. , 2008, Sleep medicine.

[10]  A. Walters,et al.  Treatment of restless legs syndrome: An evidence‐based review and implications for clinical practice , 2008, Movement disorders : official journal of the Movement Disorder Society.

[11]  W. Oertel,et al.  Efficacy of cabergoline in restless legs syndrome , 2006, Neurology.

[12]  M. Johns,et al.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale. , 1991, Sleep.

[13]  W. Paulus,et al.  Augmentation as a treatment complication of restless legs syndrome: Concept and management , 2007, Movement disorders : official journal of the Movement Disorder Society.

[14]  W. Oertel,et al.  One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. , 2008, Sleep medicine.

[15]  T. Pollmächer,et al.  Periodic leg movements (PLM): their relationship to sleep stages. , 1993, Sleep.

[16]  E. Tolosa,et al.  Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial , 2007, The Lancet Neurology.

[17]  P. Lespérance,et al.  Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: A study of 133 patients diagnosed with new standard criteria , 1997, Movement disorders : official journal of the Movement Disorder Society.

[18]  C. Guilleminault,et al.  EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. , 1992, Sleep.

[19]  Bernd Feige,et al.  Periodic leg movements in sleep and periodic limb movement disorder: prevalence, clinical significance and treatment. , 2006, Sleep medicine reviews.

[20]  Richard P Allen,et al.  Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. , 2003, Sleep medicine.

[21]  W. Zung.  The role of rating scales in the identification and management of the depressed patient in the primary care setting. , 1990, The Journal of clinical psychiatry.

[22]  C. Kushida,et al.  Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. , 2004, Sleep.

[23]  Richard P Allen,et al.  Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. , 2003, Sleep medicine.

[24]  D. Riemann,et al.  Relationship of periodic leg movements and severity of restless legs syndrome: A study in unmedicated and medicated patients , 2007, Clinical Neurophysiology.

[25]  J. Jankovic,et al.  Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease , 2007, Neurology.

[26]  W. Hening.  Current guidelines and standards of practice for restless legs syndrome. , 2007, The American journal of medicine.

[27]  R. Allen,et al.  Correlation between rating scales and sleep laboratory measurements in restless legs syndrome. , 2004, Sleep medicine.

[28]  S. Easthope,et al.  Rotigotine: in Parkinson's disease. , 2005, CNS drugs.

[29]  W. Oertel,et al.  State of the art in restless legs syndrome therapy: Practice recommendations for treating restless legs syndrome , 2007, Movement disorders : official journal of the Movement Disorder Society.

[30]  A. Walters,et al.  Rotigotine improves restless legs syndrome: A 6‐month randomized, double‐blind, placebo‐controlled trial in the United States , 2010, Movement disorders : official journal of the Movement Disorder Society.

[31]  R P Allen,et al.  Augmentation of the restless legs syndrome with carbidopa/levodopa. , 1996, Sleep.

[32]  T. Penzel,et al.  A new design of a polysomnography-based multi-center treatment study for the restless legs syndrome , 2002, Clinical Neurophysiology.

[33]  J. Montplaisir,et al.  The influence of sex, age and sleep/wake state on characteristics of periodic leg movements in restless legs syndrome patients , 1999, Clinical Neurophysiology.

[34]  A. Stewart,et al.  Measuring Functioning and Well-Being: The Medical Outcomes Study Approach , 1992 .